ZD-6126 AstraZeneca

IDrugs. 2004 Apr;7(4):380-7.

Abstract

AstraZeneca is developing ZD-6126, one of the ANG-400 series of vascular-targeting and tubulin-binding agents under license from Angiogene Pharmaceuticals Ltd, for the potential treatment of cancer.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic / statistics & numerical data
  • Drugs, Investigational / chemistry
  • Drugs, Investigational / therapeutic use*
  • Humans
  • Neoplasms / drug therapy
  • Organophosphorus Compounds / chemistry
  • Organophosphorus Compounds / therapeutic use*

Substances

  • Antineoplastic Agents
  • Drugs, Investigational
  • N-acetylcochinol-O-phosphate
  • Organophosphorus Compounds